Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview

The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview

The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview

The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview

Nirsevimab FAQs

Nirsevimab FAQs

Nirsevimab FAQs

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Гудз І.М. БЕЗПЕКА ПАЦІЄНТА ПРИ ПРОВЕДЕННІ ПОДОВЖЕНОЇ ПІСЛЯОПЕРАЦІЙНОЇ ПРОФІЛАКТИКИ ВЕНОЗНОГО ТРОМБОЕМБОЛІЗМУ

아갈시다제 베타 치료를 받은 파브리병 환자의 심장 및 뇌혈관 지표를 평가한 체계적 문헌 고찰 연구

A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta
Oudit GY, et al. Front Cardiovasc Med.  2025 Jan 21;11:1415547.